Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc

Frederick, MD, United States

Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc

Frederick, MD, United States

The Henry M. Jackson Foundation for the Advancement of Military Medicine is a private, not-for-profit organization established in 1983 and authorized by Congress to support medical research and education at the Uniformed Services University of the Health science and throughout the military medical community. The Foundation was named in honor of Washington State Senator Henry "Scoop" Jackson, who sponsored the original legislation. Senator Jackson had a long-standing commitment to military medicine and health.HJF provides scientific and management services, from infrastructure development, financial administration and clinical trials management to staffing, continuing medical education and event planning. The Foundation works with a variety of programs, from large multi-site trials to small, benchtop projects, both nationally and abroad. USU, located in Bethesda, Maryland, is the nation’s only federal school of medicine and graduate school of nursing. It was established by Congress in 1972. The University’s curriculum is similar to that of its civilian counterparts, but it also provides additional specialized education elements geared towards producing career uniformed officers. USU was a major focus of the documentary film Fighting for Life, which was released in 2008.HJF’s largest program is the U.S. Military HIV Research Program , whose mission is to protect U.S. military personnel and aid the international fight against HIV. Established in 1988, the program focuses on HIV vaccine development, prevention, disease surveillance and care and treatment for HIV.The Foundation supports more than 1,000 additional research projects at USU and throughout military medicine, including the Center for Prostate Disease Research, the Navy Biological Defense Directorate, the Center for the Study of Traumatic Stress and the Center for Disaster and Humanitarian Assistance Medicine. It employs more than 2,400 scientific, medical, management and administrative personnel. HJF also manages endowments for USU and promotes government-civilian partnerships through its Center for Public-Private Partnerships Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc | Date: 2017-08-02

Methods of detecting or diagnosing posttraumatic stress disorder (PTSD) in a human subject are disclosed. In addition, methods of monitoring the progression of PTSD in a human subject, methods of treating a patient with PTSD, kits for diagnosing PTSD in a human subject suspected of having PTSD, and methods of detecting a microRA (miRNA) or plurality of miRNAs in a biological sample from a human subject are also disclosed.


Patent
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc | Date: 2017-07-26

This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.


Patent
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc | Date: 2017-03-01

The present invention provides for methods of measuring levels of micro RNAs for the diagnosis, treatment and/or monitoring the progression of post-traumatic stress disorder (PTSD) or traumatic brain injury (TBI) in a subject having or suspected of having PTSD and/or TBI. The methods, in general comprise measuring levels of at least one of miR-142- 5p, miR-19b, miR-1928, miR-223-3p, miR-322*, miR-324, miR-421-3p, miR-463* and miR- 674* is a sample from a subject suffering from or suspected of having PTSD and/or TBI.


Patent
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc | Date: 2017-01-18

This invention relates to soluble forms of F glycoprotein from Hendra and Nipah virus and to compositions comprising soluble forms of F glycoprotein from Hendra and Nipah virus. This invention further relates to soluble oligomers of F glycoprotein from Hendra and Nipah virus. This invention also relates to nucleic acids encoding soluble forms of F glycoprotein from Hendra and Nipah virus. This invention also relates to diagnostic and therapeutic methods using the soluble forms of F glycoprotein from Hendra and Nipah virus. Further, this invention relates to antibodies, including neutralizing antibodies, and to vaccines for the prevention, diagnosis and treatment of infection by Hendra and Nipah viruses.


Patent
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc | Date: 2016-11-14

The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.


Patent
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc | Date: 2016-05-05

Provided are methods of using polycarbonate filters to isolate and detect cancer cells in a biological fluid, particularly biological fluids, such as urine, that contain very low concentrations of cancer cells. The characterization of the isolated cells for the presence or absence of cancer specific proteins is useful for cancer diagnosis and prognosis


Patent
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc | Date: 2017-04-12

The present invention generally relates to antigen-specific tolerogenic protein therapy and the use thereof for treating adverse immune responses, including those associated with autoimmune diseases such as multiple sclerosis (MS) and hemophilia. In particular, the invention involves the application of a B cell-targeting IgG fusion protein as the antigen-specific tolerogenic protein therapy, either alone or in combination with inhibitory antibodies. The fusion protein comprises a B-cell specific targeting module, the constant region of the human IgG4 heavy chain or a fragment thereof; and an antigen.


Patent
Healthpartners Research & Education and Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc | Date: 2017-02-15

The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patients CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patients nasal cavity, thereby bypassing the patients blood-brain barrier and delivering the therapeutic composition directly to the patients central nervous system.


Patent
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc | Date: 2016-12-30

This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.


Patent
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc | Date: 2017-01-18

Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.

Loading Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc collaborators
Loading Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc collaborators